CD274 and colorectal carcinoma: Programmed death receptor 1 (PD-1)/programmed death receptor ligand-1 (PD-L1) inhibitors have shown great efficacy in CRC with microsatellite instability-high (MSI-H)/deficiency mismatch repair (dMMR) in some proof-of-concept studies and phase II trials, with an objective response rate (ORR) ranging from 31.1% to 65% (11–14).